Bevacizumab · doença de Rendu-Osler-Weber · telangiectasia hemorrágica hereditária · telangiectasias · angiodisplasias · hemorragia gastrointestinal Resumo A doença de Rendu-Osler-Weber, também conhecida por telangiectasia hemorrágica hereditária, é uma doença autossómica dominante rara, frequentemente caracterizada por epistáxis recorrente, telangiectasias mucocutâ-neas e gastrointestinais e malformações arteriovenosas viscerais. Doentes com envolvimento gastrointestinal podem apresentar um amplo espectro de gravidade, que pode variar de anemia ferropénica não complicada até hemorragia persistente e refractária. Os autores apresentam o caso de uma mulher de 62 anos, admitida por anemia na sequência de vários episódios de melenas, cuja avaliação endoscópica revelou múltiplas angiodisplasias no estômago e intestino delgado. Apesar de várias tentativas de terapêutica endoscópica e médica com agentes hormonais e octreotido, evoluiu para hemorragia persistente e anemia grave, com necessidade de suporte transfusional frequente. Imediatamente após ter iniciado be- 
Introduction
Rendu-Osler-Weber disease (ROW; also known as hereditary hemorrhagic telangiectasia) is an autosomal dominant disorder which affects approximately 1 in 5,000-8,000 individuals [1] . This entity is characterized by recurrent spontaneous epistaxis, multiple mucocutaneous and gastrointestinal telangiectasias, visceral arteriovenous malformations, and familial history, features that are included in the Curaçao diagnostic criteria [2, 3] . Gastrointestinal involvement usually arises after the 5th or 6th decade of life and its management may be particularly challenging [4] . We present the case of a female patient, diagnosed with ROW 10 years earlier, who developed severe and persistent bleeding from gastrointestinal angiodysplasias. Despite having been submitted to endoscopic treatment with argon plasma coagulation (APC), hormonal therapy, and octreotide, she kept having continuous blood loss and significant transfusion requirements. Bevacizumab was started and followed by a dramatic and sustained clinical and biochemical response.
Clinical Case
A 62-year-old female was diagnosed with ROW at the age of 52 due to recurrent epistaxis, multiple mucocutaneous telangiectasias, and a positive family history. Ten years after the diagnosis, she presented to the emergency department with a recent history of fatigue, dizziness, and several episodes of melena. Laboratory studies revealed microcytic anemia (hemoglobin 4.5 g/dL, median corpuscular volume 69 fL), with low transferrin saturation (9%) and ferritin (4.1 ng/mL). She underwent an upper digestive endoscopy which described a few angiodysplasias in the gastric body and duodenum; APC was performed (Fig. 1) . Since the number of gastroduodenal vascular lesions appeared to be insufficient to justify the degree of bleeding, a capsule endoscopy was performed, revealing multiple (more than 100) angiodysplasias in the duodenum, jejunum, and ileum (Fig. 2) . Further investigation, which included colonoscopy, abdominal ultrasound, thoracic CT, and cranial MRI scans, detected no additional vascular abnormalities. Despite having been submitted to coagulation of several vascular lesions through double-balloon enteroscopy and having initiated hormonal therapy with ethinylestradiol plus norethisterone (2 + 1 mg per day), hemorrhage and anemia persisted with the need for repeated transfusion of packed red blood cells (PRBC) (Fig. 3) . Treatment with octreotide was started; however, a few hours after the first subcutaneous administration (100 μg), the patient presented with abdominal discomfort, nausea, and vomiting, leading to the discontinuation of the treatment. Given the maintenance of severe gastrointestinal bleeding, with PRBC transfusion dependence (1 unit every other day to ensure levels of 6-7 g/dL of hemoglobin), systemic therapy with bevacizumab was introduced at a dose of 7.5 mg/kg, intravenously, every 3 weeks. The patient's clinical response was immediate: since the beginning of the therapy, she had not required any transfusion support and only had one episode of melena when an infusion was postponed for 1 week due to an upper respiratory infection (Fig. 4) . After 6 weeks of treatment, the regimen was adjusted to 5 mg/kg every 3 weeks, without any change in clinical status. Currently, after 1 year of follow-up, she maintained complete clinical and biochemical remission without any adverse event.
Discussion
Gastrointestinal involvement, the second most frequent cause of bleeding in ROW patients, occurs in about one third of subjects with this condition [5] . Of those, approximately one half may develop significant disease and need regular blood transfusions [6] . The stomach and the duodenum are the most commonly affected organs [7] ; notwithstanding, small bowel angiodysplasias may be found in 56-89% of the cases [8, 9] . Although endoscopic treatment with APC may be useful for patients who do not achieve control with initial general supportive measures, the use of multiple endoscopic procedures in patients with continuous blood loss is not recommended [4] . For patients like ours, presenting with refractory bleeding and consequent severe anemia, several therapeutic possibilities were described to treat vascular lesions [10] . Hormonal therapy with an estrogen-progesterone combination proved to be beneficial in a small controlled study of 9 patients, 5 of which had ROW [11] . Nonetheless, the biggest randomized controlled trial regarding this medical option failed to show a decrease in the number of bleeding episodes and transfusion requirements in noncirrhotic subjects with gastrointestinal telangiectasias [12] . Although there are no comparative studies between them, both thalidomide and octreotide long-acting release were reported to be safe and effective for patients with gastrointestinal hemorrhage [13] [14] [15] [16] ; the latter has even reduced hospital admissions and demonstrated a cost-effective benefit in this setting [15, 16] . In spite of being a generally safe drug, adverse events such as nausea, diarrhea, and flatulence are relatively common within the first hours fol-lowing administration of octreotide [14] . Although these symptoms usually resolve after the first weeks, their occurrence may represent an additional challenge. In this case, as the patient developed gastrointestinal symptoms after the first administration of octreotide, she refused further treatment with this drug and we were not able to introduce the long-acting release formulation. Therefore, given the behavior of her disease and her intolerance to octreotide, we decided to initiate bevacizumab. This recombinant humanized monoclonal antibody is directed against the vascular endothelial growth factor, a protein which plays a critical role in the pathophysiology of ROW [17] . In addition to having been successfully applied in the management of epistaxis and in the reduction of high cardiac output in patients with severe hepatic involvement [18] , bevacizumab was shown to be effective controlling gastrointestinal bleeding in a few case reports [19] [20] [21] [22] [23] . In fact, patients who were refractory to several other medical and endoscopic approaches, and whose transfusion requirements ranged from 1 unit of PRBC every week to about 300 units in a year, all were reported to have developed a significant decrease in bleeding episodes and transfusion needs [19] [20] [21] [22] [23] . Furthermore, as in our case, authors described an extremely quick and long-term response, as well as the occurrence of early relapse following drug discontinuation [19] [20] [21] . Epperla et al. [21] published a case series comprising 5 ROW patients (4 with epistaxis and only 1 with gastrointestinal hemorrhage) who have reduced their PRBC consumption by 51-100% and their total number of emergency department visits and hospitalizations by 78%. Of note, hypertension and proteinuria were observed in 2 and 1 of those patients, respectively, during the follow-up period [21] . The optimal dose and regimen for this agent are not fully established yet. Although the majority of authors used 5 or 7.5 mg/kg every 2 or 3 weeks, successful use of low-dose bevacizumab (1 or 2 mg/kg, every 3 weeks) was already reported, which could potentially decrease drug-related costs and adverse events [22, 23] . In our patient, in whom hormonal therapy did not achieve clinical remission and who did not tolerate octreotide, intravenous bevazicumab at a dose of 5 mg/kg every 3 weeks was able to attain a dramatic and sustained response, without any complication. This case reinforces that this agent may be extremely useful for subjects who are either intolerant or refractory to alternative treatment options.
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